Skip to main content
. 2010 Dec 7;16(45):5766–5772. doi: 10.3748/wjg.v16.i45.5766

Table 2.

Clinical efficiency of newly diagnosed case

Newly diagnosed cases Tumor response evaluation1
Follow-up period (mo) Survival2
Target lesion 2 mo post-TEA Time to progress (mo)
1 CR 9.9 16.8 Yes
2 CR 6.1 14.1 Yes
3 PR 6.3 9.5 Yes
4 PR 5.1 7.5 Yes
5 PR 0 6.3 Yes
1

RECIST version 1.1;

2

Survival (yes), death (no). TEA: Transarterial embolization ablation; CR: Complete response; PR: Partial response.